Identification of highly-protective combinations of Plasmodium vivax recombinant proteins for vaccine development
View/ Open
Author
White, Michael T
He, Wen-Qiang
Hostetler, Jessica B
Brewster, Jessica
Frato, Gabriel
Malhotra, Indu
Gruszczyk, Jakub
Huon, Christele
Lin, Enmoore
Kiniboro, Benson
Yadava, Anjali
Siba, Peter
Galinski, Mary R
Healer, Julie
Chitnis, Chetan
Cowman, Alan F
Takashima, Eizo
Tsuboi, Takafumi
Tham, Wai-Hong
Fairhurst, Rick M
Rayner, Julian C
King, Christopher L
Mueller, Ivo
Published Version
https://doi.org/10.7554/elife.28673Metadata
Show full item recordCitation
França, Camila Tenorio, Michael T White, Wen-Qiang He, Jessica B Hostetler, Jessica Brewster, Gabriel Frato, Indu Malhotra, Jakub Gruszczyk, Christele Huon, Enmoore Lin, Benson Kiniboro, Anjali Yadava, Peter Siba, Mary R Galinski, Julie Healer, Chetan Chitnis, Alan F Cowman, Eizo Takashima, Takafumi Tsuboi, Wai-Hong Tham, Rick M Fairhurst, Julian C Rayner, Christopher L King, and Ivo Mueller. "Identification of Highly-protective Combinations of Recombinant Proteins for Vaccine Development." ELife 6 (2017):Abstract
The study of antigenic targets of naturally-acquired immunity is essential to identify and prioritize antigens for further functional characterization. We measured total IgG antibodies to 38 P. vivax antigens, investigating their relationship with prospective risk of malaria in a cohort of 1–3 years old Papua New Guinean children. Using simulated annealing algorithms, the potential protective efficacy of antibodies to multiple antigen-combinations, and the antibody thresholds associated with protection were investigated for the first time. High antibody levels to multiple known and newly identified proteins were strongly associated with protection (IRR 0.44–0.74, p<0.001–0.041). Among five-antigen combinations with the strongest protective effect (>90%), EBP, DBPII, RBP1a, CyRPA, and PVX_081550 were most frequently identified; several of them requiring very low antibody levels to show a protective association. These data identify individual antigens that should be prioritized for further functional testing and establish a clear path to testing a multicomponent P. vivax vaccine.Other Sources
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5655538/Terms of Use
This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#PassThruCitable link to this page
https://nrs.harvard.edu/URN-3:HUL.INSTREPOS:37371849
Collections
- SPH Scholarly Articles [6362]
Contact administrator regarding this item (to report mistakes or request changes)